IFITM2 Antibody (YA8830)(PBS only)
(Synonyms: 1-8D; DSPA2c)IFITM2 Antibody (YA8830) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFITM2.
-
Host:
Mouse
-
Isotype:
IgG2a
-
Application:
IHC-P
-
Reactivity :
Human
-
Formulation:
Supplied in PBS, pH 7.4.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|
| Dilution Ratio | 1:500-800 |
Product Details
IFITM2 Antibody (YA8830) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFITM2.
-
Host Mouse
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 14.5 kDa
Full length human recombinant protein of human IFITM2 produced in E.coli.
Affinity purified
Non-conjugated
IgG2a
Product Properties
-
Appearance
Liquid
-
Formulation
Supplied in PBS, pH 7.4.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
IFITM2 is an IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome[1][2][3][4].
-
Subcellular Localization
Cell membrane,Lysosome membrane,Late endosome membrane
-
Expression
Induction: By IFN-alpha, IFNB1/IFN-beta and IFNG/IFN-gamma. Down-regulated by p53/TP53
-
Isoforms & Post-Translational Modification
Q01629: 132 amino acids, molecular weight 14632 Da.
-
Subunit
Interacts with CD81
-
SwissProt ID
-
Synonyms
1-8D; DSPA2c
Documentation
Powered by Bioz
